Claim 70% Off TipRanks This Holiday Season
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
SciSparc Ltd. ( (SPRC) ) has shared an announcement.
On November 20, 2025, SciSparc Ltd. announced that NeuroThera Labs Inc., in collaboration with Clearmind Medicine Inc., has filed an Israeli patent application for a new non-hallucinogenic neuroplastogen treatment for depression. This filing is part of an ongoing effort to expand their intellectual property portfolio, which includes 13 patents aimed at addressing various conditions such as addiction and obesity. The development of this innovative therapy could significantly impact the treatment of depression, a condition affecting over 332 million people globally, and enhance SciSparc’s position in the pharmaceutical industry.
More about SciSparc Ltd.
SciSparc Ltd. is a clinical-stage pharmaceutical company focused on developing novel treatments for central nervous system disorders through its majority-owned subsidiary, Neurothera Labs Inc. The company specializes in cannabinoid pharmaceuticals and is involved in drug development programs targeting conditions like Tourette syndrome, Alzheimer’s disease, and autism spectrum disorder.
Average Trading Volume: 4,713,397
Technical Sentiment Signal: Sell
Current Market Cap: $3.99M
Learn more about SPRC stock on TipRanks’ Stock Analysis page.